Accéder au contenu
Merck

Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.

Journal of medicinal chemistry (2008-08-01)
Morteza Malakoutikhah, Meritxell Teixidó, Ernest Giralt
RÉSUMÉ

Several peptide families containing N-methylated amino acids were designed and synthesized using solid-phase peptide synthesis (SPPS). The permeability and phospholipophilicity of these compounds were studied by parallel artificial membrane permeability assay (PAMPA) and immobilized artificial membrane chromatography (IAMC) to select the best peptides in terms of length, terminal groups, and amino acid replacement to be used as carriers that pass through a model of the blood-brain barrier (BBB) by passive diffusion. Furthermore, the enzymatic stability of these peptides in human serum and their cell viability by MTT assay were tested. These peptide families showed great stability and nontoxicity. The three peptides that showed the greatest permeability were coupled to levodopa (a nonpassive permeating drug) and assessed. These peptides effectively transferred levodopa through an artificial membrane by means of passive diffusion.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
3,4-Dihydroxy-L-phenylalanine, ≥98% (TLC)
Sigma-Aldrich
Caféine, powder, ReagentPlus®
Sigma-Aldrich
Caféine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Carbamazepine, powder
Sigma-Aldrich
Caféine, Sigma Reference Standard, vial of 250 mg
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Sigma-Aldrich
Caféine, anhydrous, tested according to Ph. Eur.
Supelco
Caféine, traceable to primary standards (LGC)
Supelco
Caffeine solution, analytical standard, 1.0 mg/mL in methanol
Sigma-Aldrich
Caféine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Caféine, BioXtra
Sigma-Aldrich
Carbamazepine, meets USP testing specifications